Benzo nitrogen-containing heterocyclic derivative regulator, preparation method therefor and use thereof

HK40137396APending Publication Date: 2026-09-11SHANGHAI HANSOH BIOMEDICAL CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026125026
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-07-02
Filing Date
2026-06-18
Publication Date
2026-09-11
Patent Text Reader

Abstract

A benzo nitrogen-containing heterocyclic derivative regulator, a preparation method therefor and a use thereof. Particularly, the present invention relates to a compound represented by general formula (XIX), a preparation method therefor, a pharmaceutical composition containing the compound, and a use of the compound as a regulator in the preparation of drugs for treating metabolic diseases and related diseases, wherein each substituent in the general formula (XIX) is the same as the definition in the description.
Need to check novelty before this filing date? Find Prior Art

Description

VO 2 0 2 5 / 0 2 6 2 7 0 A 1 (12) International application published under the Patent Cooperation Treaty (19) International Bureau of the World Intellectual Property Organization (43) International Publication Date: 6 February 2025 (06.02.2025) (10) International Publication No.: WO 2025 / 026270 A1 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. [CN / CN]; Lianyungang Economic and Technological Development Zone, Jiangsu Province, China, 222047 (CN). (72) Inventor: Xiaofeng Mao; Building 11, No. 3728 Jinke Road, Pudong New Area (Shanghai) Pilot Free Trade Zone, Shanghai 201203 (CN). Wang Jun; Building 11, No. 3728 Jinke Road, Pudong New Area (Shanghai) Pilot Free Trade Zone, Shanghai 201203, China. Su Yidong; Building 11, No. 3728 Jinke Road, Pudong New Area (Shanghai) Pilot Free Trade Zone, Shanghai 201203, China. Yu Wensheng; Building 11, No. 3728 Jinke Road, Pudong New Area (Shanghai) Pilot Free Trade Zone, Shanghai 201203, China. WIPO PCT (51) International Patent Classification: C07D 471 / 04 (2006.01) A61P 1 / 16 (2006.01) C07D 498 / 22 (2006.01) A61P 3 / 04 (2006.01) A61K 31 / 437 (2006.01) A61P 3 / 10 (2006.01) A61K 31 / 4709 (2006.01) (21) International Application Number: PCT / CN2024 / 108192 (22) International Application Date: July 29, 2024 (29.07.2024) (25) Application Language: Chinese (26) Publication Language: Chinese (30) Priority: 202310946477.8 July 28, 2023 (28.07.2023) CN 202311087184.5 August 25, 2023 (25.08.2023) CN 202311110642.2 August 30, 2023 (30.08.2023) CN 202311269491.5 September 27, 2023 (27.09.2023) CN 202311372605.9. October 20, 2023 (20.10.2023) CN 202311546779.2 November 17, 2023 (17.11.2023) CN 202311690443.3 December 8, 2023 (08.12.2023) CN (81) 202311866263.6 December 29, 2023 (29.12.2023) CN 202410140555.X January 31, 2024 (31.01.2024) CN 202410241733.8 March 1, 2024 (01.03.2024) CN 202410385768.9 March 29, 2024 (29.03.2024) CN 202410587643.4 May 11, 2024 (11.05.2024) CN 202410882329.9 July 2, 2024 (02.07.2024) CN (71) Applicant: Shanghai Hansoh Biomedical Co., Ltd. [CN / CN]; Building 11, No. 3728 Jinke Road, Pudong New Area (Shanghai) Pilot Free Trade Zone, Shanghai 201203, China (CN). Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (74) Agent: GE CHENG & CO., LTD; 10th Floor, East Third Office Building, Oriental Plaza, No. 1 East Chang'an Street, Dongcheng District, Beijing 100738, China (CN). Designated countries (unless otherwise specified, each requiring national protection): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ.IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW (54) Title: BENZO NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF (54) Title of Invention: A benzo nitrogen-containing heterocyclic derivative regulator, a preparation method therefor and a use thereof R13 R R14 0 BE 16 (XIX) R (57) Abstract: A benzo nitrogen-containing heterocyclic derivative regulator, a preparation method therefor and a use thereof.Particularly, the present invention relates to a compound represented by general formula (XIX), a preparation method therefor, a pharmaceutical composition containing the compound, and a use of the compound as a regulator in the preparation of drugs for treating metabolic diseases and related diseases, wherein each substituent in the general formula (XIX) is the same as the definition in the description. (57) Abstract: A benzo[a] nitrogen-containing heterocyclic derivative regulator, its preparation method and application. In particular, it relates to a compound represented by general formula (XIX), its preparation method and a pharmaceutical composition containing the compound, and its use as a regulator in the preparation of drugs for treating metabolic diseases and related diseases, wherein each substituent in the general formula (XIX) is the same as the definition in the description. [See continued page] WO 2025 / 026270 A1 (84) Designated countries (unless otherwise specified, each of the available regional protections is required): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), (AM, AZ, BY, KG, KZ, RU, TJ, TM), Europe (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG) This International Announcement includes: - International Search Reports (Article 21(3) of the Treaty).

Claims

1. A compound represented by a general formula (XIX), a prodrug thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof: R13 is selected from C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl, 5-10 membered heteroaryl, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl or C2-6 alkynyl, the C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl, 5-10 heteroaryl, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl or C2-6 alkynyl are optionally further substituted by one or more substituents selected from deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; L1, L2 or L3 are each independently selected from a bond, C2-4 alkenylene, C2-4 alkynylene or -(CH2)n1-; ring A is selected from C3-14 cycloalkyl, 3-14 membered heterocyclyl, C6-14 aryl or 5-14 membered heteroaryl; ring B is selected from C3-12 cycloalkyl, 3-12 membered heterocyclyl, C6-14 aryl or 5-14 membered heteroaryl, which are optionally further substituted with one or more substituents selected from deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy or C1-6 deuterated haloalkoxy; ring C is selected from C3-14 cycloalkyl, 3-14 membered heterocyclyl, C6-14 aryl or 5-14 membered heteroaryl, which are optionally further substituted by one or more substituents selected from deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy or C1-6 deuterated haloalkoxy; ring D is selected from C3-12 cycloalkyl, 3-12 membered heterocyclyl, C6-14 aryl or 5-14 membered heteroaryl; ring E is selected from C3-14 cycloalkyl, 3-14 membered heterocyclyl, C6-14 aryl or 5-14 membered heteroaryl, which are optionally further substituted with one or more substituents selected from deuterium, halogen, amino, nitro, hydroxy, cyano, oxo, thio, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; R1, R3, R4, R5, R6, R7, R8, R9, R14, R15 or R16 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, -(CH2)m1ORc1 or (=C)Rc3Rc4, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl, 5-10 membered heteroaryl, -(CH2)m1ORc1 or (=C)Rc3Rc4 are optionally further substituted by one or more of deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; Rc1, Rc3 or Rc4 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, -(CH2)m2ORc2, -(CH2)m3C(O)NRa1Rb1 or -(CH2)m4C(O)ORa2, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl, 5-10 membered heteroaryl, -(CH2)m2ORc2, - (CH2)m3C(O)NRa1Rb1 or -(CH2)m4C(O)ORa2, are optionally further substituted by one or more of deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; Ra1, Ra2, Rb1 or Rc2 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl are optionally further substituted by one or more of deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; alternatively, R9 or R16 are respectively linked to atoms connected thereto to form C3-10 cycloalkyl, 3-10 membered heterocyclic, C6-12 aryl or 5-12 membered heteroaryl; preferably, R9 or R16 are linked to the atoms connected thereto to form C3-6 cycloalkyl, 3-6 membered heterocyclic containing 1-3 atoms selected from N, O or S, C6-10 aryl, or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S; more preferably, R9 or R16 are linked to the atoms connected thereto to form cyclopropyl; alternatively, when n is not 1, R1 and R1, R4 and R5, R5 and R6, R7 and R8 are linked to the atoms connected thereto to form C3-10 cycloalkyl, 3-10 membered heterocyclic, C6-12 aryl or 5-12 membered heteroaryl, which are optionally further substituted by one or more substituents selected from deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; n, n1, ml, m2, m3 or m4 is each independently selected from 0, 1, 2, 3, 4 or 5.

2. The compound, the prodrug thereof, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, characterized in that the general formula (XIX) is further represented by a general formula (XVIII): wherein, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R12, R14, R15 or R16 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 deuterated haloalkyl, C1-3 hydroxyalkyl, C1-3 deuterated hydroxyalkyl, C1-3 sulfanyl, C1-3 deuterated sulfanyl, C1-3 alkoxy, C1-3 deuterated alkoxy, C1-3 haloalkoxy, C1-3 deuterated haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C3-10 aryl, 5-8 -(CH2)m1ORc1, the amino, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 deuterated haloalkyl, C1-3 hydroxyalkyl, C1-3 deuterated hydroxyalkyl, C1-3 sulfanyl, C1-3 deuterated sulfanyl, C1-3 alkoxy, C1-3 deuterated alkoxy, C1-3 haloalkoxy, C1-3 deuterated haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclic, C6-10 aryl, 5-8 membered heteroaryl or -(CH2)m1ORc1, are optionally further substituted by one or more substituents selected from deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 deuterated haloalkyl, C1-3 hydroxyalkyl, C1-3 deuterated hydroxyalkyl, C1-3 sulfanyl, C1-3 deuterated sulfanyl, C1-3 alkoxy, C1-3 deuterated alkoxy, C1-3 haloalkoxy, C1-3 deuterated haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C6-10 aryl or 5-8 membered heteroaryl; Rc1 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 deuterated haloalkyl, C1-3 hydroxyalkyl, C1-3 deuterated hydroxyalkyl, C1-3 sulfanyl, C1-3 deuterated sulfanyl, C1-3 alkoxy, C1-3 deuterated alkoxy, C1-3 haloalkoxy, C1-3 deuterated haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C6-10 aryl, 5-8 membered heteroaryl, -(CH2)m2ORc2, - (CH2)m3C(O)NRa1Rb1 or -(CH2)m4C(O)ORa2, the amino, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 deuterated haloalkyl, C1-3 hydroxyalkyl, C1-3 deuterated hydroxyalkyl, C1-3 sulfanyl, C1-3 deuterated sulfanyl, C1-3 alkoxy, C1-3 deuterated alkoxy, C1-3 haloalkoxy, C1-3 deuterated haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclic, C6-10 aryl, 5-8 membered heteroaryl, -(CH2)m2ORc2, -(CH2)m3C(O)NRa1Rb1 or - (CH2)m4C(O)ORa2 are optionally further substituted by one or more substituents selected from deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 deuterated haloalkyl, C1-3 hydroxyalkyl, C1-3 deuterated hydroxyalkyl, C1-3 sulfanyl, C1-3 deuterated sulfanyl, C1-3 alkoxy, C1-3 deuterated alkoxy, C1-3 haloalkoxy, C1-3 deuterated haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C6-10 aryl or 5-8 membered heteroaryl; Ra1, Ra2, Rb1 or Rc2 are each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 deuterated haloalkyl, C1-3 hydroxyalkyl, C1-3 deuterated hydroxyalkyl, C1-3 sulfanyl, C1-3 deuterated sulfanyl, C1-3 alkoxy, C1-3 deuterated alkoxy, C1-3 haloalkoxy, C1-3 deuterated haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C6-10 aryl or 5-8 membered heteroaryl, the amino, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 deuterated haloalkyl, C1-3 hydroxyalkyl, C1-3 deuterated hydroxyalkyl, C1-3 sulfanyl, C1-3 deuterated sulfanyl, C1-3 alkoxy, C1-3 deuterated alkoxy, C1-3 haloalkoxy, C1-3 deuterated haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclic, C6-10 aryl or 5-8 membered heteroaryl are optionally further substituted with one or more substituents selected from deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 deuterated haloalkyl, C1-3 hydroxyalkyl, C1-3 deuterated hydroxyalkyl, C1-3 sulfanyl, C1-3 deuterated sulfanyl, C1-3 alkoxy, C1-3 deuterated alkoxy, C1-3 haloalkoxy, C1-3 deuterated haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C6-10 aryl or 5-8 membered heteroaryl; alternatively, R1 and R10, R2 and R12, R4 and R5, R5 and R6, R7 and R8, R10 and R12 are linked to the atoms connected thereto to form C3-6 cycloalkyl, 3-6 membered heterocyclic containing 1-3 atoms selected from N, O or S, C6-10 aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, which are optionally further substituted with one or more substituents selected from deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 deuterated haloalkyl, C1-3 hydroxyalkyl, C1-3 deuterated hydroxyalkyl, C1-3 sulfanyl, C1-3 deuterated sulfanyl, C1-3 alkoxy, C1-3 deuterated alkoxy, C1-3 haloalkoxy, C1-3 deuterated haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C6-10 aryl or 5-8 membered heteroaryl; preferably, R1 and R10, R2 and R12, R4 and R5, R5 and R6, R7 and R8, R10 and R12 are linked to the atoms connected thereto to form cyclopropyl, which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, amino, nitro, hydroxyl, cyano, oxo, thioxo, methyl or ethyl; R13, L1, L2, L3, ring A, ring B, ring C, ring E are as set forth in claim 1; n1, ml, m2, m3 or m4 is each independently selected from 0, 1, 2, 3, 4 or 5.

3. The compound, the prodrug thereof, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 2, characterized in that, R13 is selected from C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl, C1-6 deuterated alkyl, C1-6 deuterated halogenated alkyl, C1-6 deuterated hydroxyalkyl, C1-6 deuterated alkoxy or C1-6 deuterated halogenated alkoxy, the C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl, 5-10 membered heteroaryl, C1-6 deuterated alkyl, C1-6 deuterated halogenated alkyl, C1-6 deuterated hydroxyalkyl, C1-6 deuterated alkoxy or C1-6 deuterated halogenated alkoxy are optionally further substituted with one or more substituents selected from deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; preferably, R13 is selected from C3-6 cycloalkyl, 3-6 membered heterocyclic, C6-10 aryl, 5-8 membered heteroaryl, C1-3 deuterated alkyl, C1-3 deuterated halogenated alkyl, C1-3 deuterated hydroxyalkyl, C1-3 deuterated sulfanyl, C1-3 deuterated alkoxy or C1-3 deuterated halogenated alkoxy, the C3-6 cycloalkyl, 3-6 membered heterocyclic, C6-10 aryl, 5-8 membered heteroaryl, C1-3 deuterated alkyl, C1-3 deuterated halogenated alkyl, C1-3 deuterated hydroxyalkyl, C1-3 deuterated sulfanyl, C1-3 deuterated alkoxy or C1-3 deuterated halogenated alkoxy are optionally further substituted with one or more substituents selected from deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 alkoxy, C1-3 haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C6-10 aryl or 5-8 membered heteroaryl; more preferably, R13 is selected from cyclopropyl or -CD3, wherein the cyclopropyl or - CD3 is optionally further substituted with one or more substituents selected from deuterium, halogen, or C1-3 alkyl; further preferably, R13 is selected from cyclopropyl, and the cyclopropyl is optionally further substituted by one or more substituents selected from deuterium, halogen, or C1-3 alkyl.

4. The compound, the prodrug thereof, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 2, characterized in that the general formula (XVIII) is further shown in a general formula (XVIII-A): alternatively, the general formula (XVIII) is further shown in a general formula (XVIII-B): wherein, ring A, ring B, ring C, ring E, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R12, R14, R15, R16, L1, L2 and L3 are as defined in claim 2.

5. The compound, the prodrug thereof, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, characterized in that the general formula (XIX) is further shown in a general formula (V): wherein, R4, R5 or R6 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 sulfanyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 sulfanyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl and 5-10 membered heteroaryl are optionally further substituted with one or more substituents selected from halogen, amino, nitro, hydroxy, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl and 5-10 membered heteroaryl; preferably, R4, R5 or R6 is each independently selected from hydrogen, deuterium, halogen, amino, cyano, C1-3 alkyl, C1-3 sulfanyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclic containing 1-3 N, O or S atoms, which are optionally further substituted by one or more substituents selected from halogen, C1-3 alkyl, C1-3 deuterated alkyl and C1-3 alkoxy; more preferably, R4, R5 or R6 is each independently selected from fluorine, methyl, cyano, ethynyl, methylthio, amino, cyclopropyl, oxetane, which are optionally further substituted by halogen, methoxy, deuterated methyl; alternatively, R5 and R6 are linked to form C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl, the C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl and 5-10 membered heteroaryl are optionally further substituted by one or more of halogen, amino, nitro, hydroxy, C1-6 cyanoalkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 sulfanyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl and 5-10 membered heteroaryl; R3 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, -NS(O)Ra1Rb1, -(CH2)n1S(O)NRa2Rb2, -P(O)Ra3Rb3, -NRa5S(O)NRa4Rb4, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl and 5-10 membered heteroaryl are optionally further substituted by one or more of halogen, amino, nitro, hydroxyl, cyano, oxo, -NS(O)Ra1Rb1, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl and 5-10 membered heteroaryl; Ra1, Rb1, Ra2, Rb2, Ra3, Rb3, Ra4, Rb4 or Ra5 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl; alternatively, Ra1 and Rb1, Ra2 and Rb2, Ra3 and Rb3, Ra4 and Rb4 are linked to form C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl, the C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl and 5-10 membered heteroaryl are optionally further substituted by one or more substituents selected from halogen, aminonitrocyanocyano C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl and 5-10 membered heteroaryl; preferably, Ra1 and Rb1, Ra2 and Rb2, Ra3 and Rb3, Ra4 and Rb4 are linked to form C3-8 cycloalkyl, 3-6 membered heterocyclic, C6-10 aryl or 5-8 membered heteroaryl; R7, R8, R9 or R10 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl, which are optionally further substituted by one or more of halogen, amino, nitro, hydroxy, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl and 5-10 membered heteroaryl; R12 is selected from C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl or C2-6 alkynyl, which are optionally further substituted by one or more of halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, and 5-10 membered heteroaryl; n1 is an integer of 0-5; wherein when R7 and R8 are hydrogen, R9, R10, and R12 are methyl, and R3 and R5 are fluorine, R4 and R6 are not methyl at the same time; when R7 and R8 are hydrogen, R9, R10, and R12 are methyl, R3 is hydrogen, and R5 is halogen, R4 and R6 are not methyl at the same time; when R7, R8, R9, R10, and R12 are methyl, R5 is fluorine, and R4 is halogen, trifluoromethyl, or cyclopropane, R6 is not hydrogen; when R7, R8, R9, R10 are methyl, R12 is deuterated methyl, R3 is fluorine, R5 is halogen, R4 is deuterated methyl, R6 is not deuterated methyl; when R4, R6, R7, R8, R9, R10 are methyl, R3, R5 are fluorine, R12 is not deuterated methyl; when R7, R8, R9, R10, R12 are methyl, R3 is fluorine, R5 is halogen, R4 is methyl, R6 is not methyl; when R7, R8, R9, R10 are methyl, R12 is deuterated methyl, R3 is fluorine, R5 is halogen, and R4 is deuterated methyl, R6 is not a deuterated methyl; when R4, R6, R7, R8, R9, R10 are methyl, R3 and R5 are fluorine, R12 is not deuterated methyl.

6. The compound, the prodrug thereof, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, characterized in that the general formula (XIX) is further shown in a general formula (V): wherein, R4, R5 or R6 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 sulfanyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 sulfanyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl and 5-10 membered heteroaryl are optionally further substituted with one or more substituents selected from halogen, amino, nitro, hydroxy, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl and 5-10 membered heteroaryl; preferably, R4, R5 or R6 is each independently selected from hydrogen, deuterium, halogen, amino, cyano, C1-3 alkyl, C1-3 sulfanyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclic containing 1-3 N, O or S atoms, which are optionally further substituted by one or more substituents selected from halogen, C1-3 alkyl, C1-3 deuterated alkyl and C1-3 alkoxy; more preferably, R4, R5 or R6 is each independently selected from fluorine, methyl, cyano, ethynyl, methylthio, amino, cyclopropyl, oxetane, which are optionally further substituted by halogen, methoxy, deuterated methyl; alternatively, R5 and R6 are linked with adjacent atoms to form a C3-8 cycloalkyl, a 3-8 membered heterocyclyl, a C6-10 aryl or a 5-10 membered heteroaryl, the C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl are optionally further substituted by one or more substituents of halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 sulfanyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; R3 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, -NS(O)Ra1Rb1, -(CH2)n1S(O)NRa2Rb2, -P(O)Ra3Rb3, -NRa5S(O)NRa4Rb4, - (CH2)n2Ra5Rb5 or the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxy, cyano, oxo, - NS(O)Ra1Rb1, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; Ra1, Rb1, Ra2, Rb2, Ra3, Rb3, Ra4, Rb4, Ra5, Rb5, Ra6, or Rb6 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl; alternatively, Ra1 and Rb1, Ra2 and Rb2, Ra3 and Rb3, Ra4 and Rb4, Ra5 and Rb5, Ra6 and Rb6 are linked to adjacent atoms to form C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl, and the C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl, which are optionally further substituted by one or more substituents of halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; R7, R8, R9 or R10 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl or -(CH2)m1ORc1, which are optionally further substituted with one or more substituents selected from halogen, amino, nitro, hydroxy, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; preferably, R7, R8, R9 or R10 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 alkoxy, C1-3 haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C6-10 aryl, 5-8 membered heteroaryl or -(CH2)m1ORc1, which are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxy, cyano, oxo, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 alkoxy, C1-3 haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C6-10 aryl or 5-8 membered heteroaryl; Rc1 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 sulfanyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, or 5-10 membered heteroaryl, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 sulfanyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl are optionally further substituted with one or more substituents selected from halogen, amino, nitro, hydroxy, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; preferably, Rc1 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 sulfanyl, C1-3 alkoxy, C1-3 haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C6-10 aryl or 5-8 membered heteroaryl, which are optionally further substituted with one or more substituents selected from halogen, amino, nitro, hydroxy, cyano, oxo, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 alkoxy, C1-3 haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C6-10 aryl or 5-8 membered heteroaryl; alternatively, R7, R8, R9 or R10 is linked to the atoms connected thereto to form C3-10 cycloalkyl, 3-10 membered heterocyclyl, C6-12 aryl, or a 5-12 membered heteroaryl; R12 is selected from C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl or C2-6 alkynyl, -(CH2)n2Ra5Rb5 or which are optionally further substituted by one or more of halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, and 5-10 membered heteroaryl; alternatively, R10 is linked to the atoms connected thereto and the adjacent atoms to form C3-10 cycloalkyl, 3-10 membered heterocyclic, C6-12 aryl, or 5-12 membered heteroaryl; preferably, R10 is linked to the atoms connected thereto and the adjacent atoms to form C3-6 cycloalkyl, 3-6 membered heterocyclic, C6-10 aryl or a 5-8 membered heteroaryl; more preferably, R10 is linked to the atoms connected thereto and the adjacent atoms to form n1-n3 are integers from 0 to 5; m1 is an integer from 0 to 5.

7. The compound, the prodrug thereof, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound has a structure as follows:

8. A compound represented by a general formula (XVI), a prodrug thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof: wherein, ring F is selected from 3-18 membered heterocyclyl, C3-18 cycloalkyl, C6-18 aryl or 5-18 membered heteroaryl; preferably, ring F is selected from 3-14 membered heterocyclyl containing 1-3 heteroatoms selected from N, O or S, C3-12 cycloalkyl, C6-14 aryl or 5-14 membered heteroaryl containing 1-3 heteroatoms selected from N, O or S; more preferably, ring F is selected from 5-14 membered heterocyclyl containing 1-3 heteroatoms selected from N, O or S, C3-10 cycloalkyl, C6-10 aryl or 5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O or S; further preferably, ring F is selected from 8-14 membered tricyclic fused heterocyclic containing 1-5 heteroatoms, C3-6 bridged cycloalkyl, 3-8 membered bridged heterocyclic containing 1-3 heteroatoms, fused heterocyclic containing 1-3 heteroatoms, bridged heterocyclic containing 1-3 heteroatoms, C6-10 aryl or 5-10 membered fused heteroaryl containing 1-3 heteroatoms; furthermore preferably, ring F is selected from phenyl, pyridyl, pyrimidinyl, thiazolyl, pyridazinyl, oxazolyl, morpholinyl, ring B is selected from C3-12 cycloalkyl, 3-12 membered heterocyclyl, C6-14 aryl or 5-14 membered heteroaryl, which are optionally further substituted with one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy or C1-6 deuterated haloalkoxy; ring C is selected from C3-12 cycloalkyl, 3-12 membered heterocyclyl, C6-14 aryl or 5-14 membered heteroaryl, which are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy or C1-6 deuterated haloalkoxy; ring E is selected from C3-12 cycloalkyl, 3-12 membered heterocyclyl, C6-14 aryl or 5-14 membered heteroaryl, which are optionally further substituted by one or more substituents selected from deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 sulfanyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; L1, L2 or L3 are each independently selected from a bond, C2-4 alkenylene, C2-4 alkynylene, -(CH2)n1- or -(CH2)n5NRb5, which are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; R1 is independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl, 5-10 membered heteroaryl, -NS(O)Ra1Rb1, -(CH2)n1S(O)NRa2Rb2, - P(O)Ra3Rb3, -NRa5S(O)NRa4Rb4 , -(CH2)n1O(CH2)n2Ra5 , -(CH2)n1C(O)NRa6Rb6 , - (CH2)n1P(O)Ra3Rb3, -(CH2)n1NRa8C(O)Rb8, -(CRa8Rb8)n4C(O)NRa9Rb9, - (CH2)n1S(O)2Rb5 or -(CH2)n5C(O)NRa10Rb10, which are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, - NS(O)Ra1Rb1, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heteroaryl, C6-10 aryl or 5-10 membered heteroaryl; alternatively, R1 is respectively linked to the atoms connected thereto to form C3-12 cycloalkyl, 3-12 membered heterocyclic, C6-14 aryl or 5-14 membered heteroaryl, which are optionally further substituted by one or more substituents selected from deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl, 5-10 membered heteroaryl, -NS(O)Ra1Rb1, - (CH2)n1S(O)NRa2Rb2, -P(O)Ra3Rb3, -NRa5S(O)NRa4Rb4, -(CH2)n1S(O)2Ra5, -(CH2)n1O(CH2)n2Rb5, -(CH2)n1NRa8C(O)Rb8, -(CRa8Rb8)n4C(O)NRa9Rb9, -(CH2)n1S(O)2Rb5 or -(CH2)n5C(O)NRa10Rb10; Ra1, Rb1, Ra2, Rb2, Ra3, Rb3, Ra4, Rb4, Ra5, Ra6, Rb6, Ra7, Rb7, Ra8, Rb8, Ra9, Rb9, Ra10 or Rb10 are each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl, which are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, -NS(O)Ra1Rb1, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; alternatively, Ra1 and Rb1, Ra2 and Rb2, Ra3 and Rb3, Ra4 and Rb4, Ra6 and Rb6, Ra8 and Rb8, Ra9 and Rb9, Ra10 and Rb10 are linked with adjacent atoms to form C3-10 cycloalkyl, 3-10 membered heterocyclic, C6-12 aryl or 5-12 membered heteroaryl, which are optionally further substituted by one or more substituents selected from halogen, amino, nitro, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl; R4, R5 or R6 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl, which are optionally further substituted by one or more substituents selected from Halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl; R7, R8, R9, R10, R12, R13, R14 or R15 are each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl or - (CH2)m1ORc1, which are optionally further substituted by one or more substituents selected from deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl; Rc1 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 sulfanyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl, which are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; alternatively, R7, R8, R9, R10, R12, R13, R14 or R15 are linked to the atoms connected thereto to form a C3-10 cycloalkyl, a 3-10 membered heterocyclic, a C6-12 aryl, or 5-12 membered heteroaryl; alternatively, R10 and R12 are linked to the atoms connected thereto to form C3-10 cycloalkyl, 3-10 membered heterocyclic, C6-12 aryl or 5-12 membered heteroaryl; preferably, R10 and R12 are linked to the atoms to form C3-8 cycloalkyl, 3-8 membered heterocyclic containing 1-3 N, O or S atoms, C6-10 aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms; n1-n5, m1 or x are each independently selected from 0, 1, 2, 3, 4 or 5.

9. The compound, the prodrug thereof, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 8, characterized in that the general formula (XVI) is further represented by a general formula (XVI-A): wherein, is further as shown in which are optionally further substituted by one or more substituents selected from halogen, methoxy, C1-3 cycloalkyl, C3-6 cycloalkyl or deuterated methyl; ring M1, ring M2, ring M3, ring M4, ring M5, ring M6, ring M7, ring M8, M9 or M10 are each independently selected from C3-12 cycloalkyl, 3-12 membered heterocyclyl, C6-12 aryl or 5-12 membered heteroaryl, which are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 deuterated haloalkyl, C1-6 hydroxyalkyl, C1-6 deuterated hydroxyalkyl, C1-6 sulfanyl, C1-6 deuterated sulfanyl, C1-6 alkoxy, C1-6 deuterated alkoxy, C1-6 haloalkoxy, C1-6 deuterated haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; preferably, ring M2, ring M3, ring M4, ring M5, ring M6, ring M7, ring M8, M9 or M10 are each independently selected from C3-8 cycloalkyl, 3-8 membered heterocyclic containing 1-3 N, O or S atoms, C6-10 aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms, which are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 deuterated haloalkyl, C1-3 hydroxyalkyl, C1-3 deuterated hydroxyalkyl, C1-3 sulfanyl, C1-3 deuterated sulfanyl, C1-3 alkoxy, C1-3 deuterated alkoxy, C1-3 haloalkoxy, C1-3 deuterated haloalkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3-6 membered heterocyclyl, C6-10 aryl or 5-8 membered heteroaryl; further preferably, ring M2, ring M3, ring M4, ring M5, ring M6, ring M7, ring M8, M9 or M10 are each independently selected from C3-6 cycloalkyl, 3-6 membered heterocyclic containing 1-3 N, O or S atoms, C6-10 aryl or 5-8 membered heteroaryl containing 1-3 N, O or S atoms, which are optionally further substituted by one or more substituents selected from halogen, methoxy, C1-3 cycloalkyl, C3-6 cycloalkyl or deuterated methyl; the definitions of ring B, ring C, ring E, L1, L2, L3, R4, R5, R6, R7, R8, R9, R10, R12, R13 and R14 are as set forth in claim 9.

10. The compound, the prodrug thereof, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 8, characterized in that the general formula (XVI) is further represented by a general formula (II): wherein, R1 and R2, R1 and R11 are linked to adjacent atoms to form C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl, the C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl; preferably, R1 and R2, R1 and R11 are linked to adjacent atoms to form C3-6 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-8 membered heteroaryl, which are optionally further substituted by one or more substituents selected from halogen, amino or oxo; more preferably, R1 and R2, R1 and R11 are linked to adjacent atoms to form 5-7 membered heterocyclic containing 1-3 selected from N, O or S, and optionally further substituted by oxo; R3 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, -NS(O)Ra1Rb1, -(CH2)n1S(O)NRa2Rb2, -P(O) Ra3Rb3 or -NRa5S(O)NRa4Rb4, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, -NS(O)Ra1Rb1, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl; Ra1, Rb1, Ra2, Rb2, Ra3, Rb3, Ra4 or Rb4 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; alternatively, Ra1, Rb1, Ra2, Rb2, Ra3, Rb3, Ra4 or Rb4 is linked to adjacent atoms to form C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl, the C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl; alternatively, Ra1, Rb1, Ra2, Rb2, Ra3, Rb3, Ra4 or Rb4 is linked to adjacent atoms to form C3-8 cycloalkyl, 3-6 membered heterocyclyl, C6-10 aryl or 5-8 membered heteroaryl; R4, R5 or R6 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl; R7, R8, R9 or R10 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl, which are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl; n1 is an integer from 0 to 5.

11. The compound, the prodrug thereof, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 8, characterized in that the general formula (XVI) is further represented by a general formula (II): wherein, R1 and R2, R1 and R11 are linked to adjacent atoms to form C3-12 cycloalkyl, 3-12 membered heterocyclic, C6-14 aryl or 5-14 membered heteroaryl, the C3-12 cycloalkyl, 3-12 membered heterocyclic, C6-14 aryl or 5-14 membered heteroaryl are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl; preferably, R1 and R2, R1 and R11 are linked to adjacent atoms to form C3-6 cycloalkyl, 3-10 membered heterocyclyl, C6-10 aryl or 5-8 membered heteroaryl, which are optionally further substituted by one or more substituents selected from halogen, C1-3 alkyl, C3-6 cycloalkyl, amino or oxo; more preferably, R1 and R2, R1 and R11 are linked to adjacent atoms to form 5-7 membered heterocyclic containing 1-3 selected from N, O or S, which are optionally further substituted by C3-6 cycloalkyl, oxo; furthermore preferably, R1 and R2, R1 and R11 are linked to adjacent atoms to form which are optionally further substituted with one or more substituents selected from halogen, C1-3 alkyl, C1-3 deuterated alkyl, C3-6 cycloalkyl, amino or oxo; R1, R2, R3 or R11 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, -NS(O)Ra1Rb1, -(CH2)n1S(O)NRa2Rb2, -P(O) Ra3Rb3 or - NRa5S(O)NRa4Rb4, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 Alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl, which are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, - NS(O)Ra1Rb1, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl; Ra1, Rb1, Ra2, Rb2, Ra3, Rb3, Ra4 or Rb4 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl; alternatively, Ra1, Rb1, Ra2, Rb2, Ra3, Rb3, Ra4 or Rb4 is respectively linked to adjacent atoms to form C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl, the C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl; R4, R5 or R6 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl, or 5-10 membered heteroaryl, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl; R7, R8, R9 or R10 is each independently selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl or -(CH2)m1ORc1, which are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl; Rc1 is selected from hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 sulfanyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 sulfanyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, C6-10 aryl or 5-10 membered heteroaryl, which are optionally further substituted by one or more substituents selected from halogen, amino, nitro, hydroxyl, cyano, oxo, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclic, C6-10 aryl or 5-10 membered heteroaryl; alternatively, R10 is linked to and the atoms connected thereto and adjacent atoms to form C3-10 cycloalkyl, 3-10 membered heterocyclic, C6-12 aryl or a 5-12 membered heteroaryl; n1 is an integer of 0-5; m1 is an integer of 0-5.

12. The compound, the prodrug thereof, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to any one of claims 8-11, wherein the compound structure is as follows:

13. A compound represented by the general formula (IN-A), (IN-B) or (IN-C), a prodrug thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof: wherein, in the general formula (IN-A), R13 is selected from C3-8 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl; the C3-8 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, which are optionally further substituted by one or more substituents selected from deuterium, halogen, amino, nitro, hydroxyl, cyano, oxy, C1-6 alkyl; ring A, ring B, L1, L2, R3, R4, R5, R6, R9 are as defined in claim 1; in the general formula (IN-B), ring D is selected from C3-8 bicyclic cycloalkyl, 3-8 membered bicyclic heterocyclic or 5-10 membered bicyclic heteroaryl containing 1-3 atoms selected from N, O or S; ring C, ring E, L3, R1, R7, R8, R14, R15, n are as defined in claim 1; in the general formula (IN-C), ring F is selected from 8-14 membered tricyclic fused heterocyclic containing 1-5 heteroatoms; ring B, L1, L2, R1, R4, R5, R6, R9, and x are as defined in claim 8.

14. A method for preparing a compound of the general formula as set forth in claims 1-12, characterized in that the method comprises the following steps: wherein: ring A, ring B, ring C, ring D, ring E, L1, L2, L3, R1, R4, R5, R6, R7, R8, R9, R13, R14, R15, and R16 are as defined in claim 1; general formula (IN-A) and general formula (IN-B) react under the action of a condensing agent and a base to obtain the general formula (XIX); the condensing agent is selected from EDC, DIC, DCC, TBTU, HATU, HBTU, HCTU, DEPBT, PyBOP or PyAOP, and preferably HATU; the base is selected from DIPEA, DIEA, Et3N, NMP, DBU or DABCO, and preferably DIPEA; alternatively, the method comprises the following steps: wherein: ring F, ring B, ring C, ring E, L1, L2, L3, R1, R4, R5, R6, R7, R8, R9, R10, R12, R13, R14, and x are as described in claim 8; general formula (IN-C) and general formula (IN-D) react under the action of a condensing agent and a base to obtain the general formula (XVI); the condensing agent is selected from EDC, DIC, DCC, TBTU, HATU, HBTU, HCTU, DEPBT, PyBOP or PyAOP, and preferably HATU; the base is selected from DIPEA, DIEA, Et3N, NMP, DBU or DABCO, and preferably DIEA.

15. A pharmaceutical composition, comprising a therapeutically effective dose of the compound as set forth in any one of claims 1-12, a prodrug thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients.

16. Use of the compound according to any one of claims 1-12, a prodrug thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 15 in the preparation of a GLP-1 receptor agonist drug.

17. Use of the compound according to any one of claims 1-12, a prodrug thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 15 in the preparation of a medicament for treating metabolic-related diseases; the disease is selected from diabetes, obesity or non-alcoholic fatty liver disease-related diseases, or other related diseases caused by diabetes, obesity or non-alcoholic fatty liver disease.